Related Experiment Video
Updated: Jul 17, 2026
06:17
Expression and Purification of Virus-like Particles for Vaccination
Published on: June 2, 2016
Regulations and procedures in parasite vaccine development
Th P M Schetters1, M Gravendyck
1Parasitology R&D Department, Intervet International, P.O. Box 31, 5830 AA, Boxmeer, The Netherlands. theo.schetters@intervet.com
Parasitology
|February 6, 2007
Summary
Regulatory hurdles often prevent parasite vaccines from reaching the market. This review details the complex regulations for medicinal products, focusing on vaccine quality, safety, and efficacy to ensure market approval.
Area of Science:
- Veterinary Parasitology
- Vaccinology
- Regulatory Science
Background:
- Numerous immunisation protocols for parasitic diseases exist, yet market entry remains a challenge.
- Understanding regulatory pathways is crucial for the successful commercialization of parasite vaccines.
Purpose of the Study:
- To present an overview of the regulations and procedures for licensing medicinal preparations, specifically parasite vaccines.
- To highlight key regulatory considerations for vaccine developers and manufacturers.
Main Methods:
- Review of existing regulations and guidelines for medicinal product licensing.
- Analysis of regulatory requirements concerning product quality, safety, efficacy, and production consistency.
- Discussion of data requirements for substantiating product claims.
Main Results:
- Licensing requires adherence to stringent regulations on product attributes (quality, safety, efficacy, potency) and production standards (facilities, consistency).
- Extensive research and development, including experimental data, are necessary to meet regulatory demands.
- Different vaccine types (live, killed, subunit) present unique regulatory challenges.
Conclusions:
- Navigating complex regulatory landscapes is essential for parasite vaccine development and market approval.
- Compliance with rigorous standards for product and production is paramount.
- Specific vaccine technologies require tailored approaches to meet regulatory expectations.
Related Concept Videos
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:29Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.